Intensity Therapeutics Announces 1-for-25 Reverse Stock Split to Regain Nasdaq Compliance

summarizeSummary

Intensity Therapeutics, Inc. will implement a 1-for-25 reverse stock split to increase its per-share trading price and regain compliance with Nasdaq's minimum bid price requirement, effective February 18, 2026.

check_boxKey Events

• 1-for-25 Reverse Stock Split Approved

  The company filed an amendment to its certificate of incorporation to effect a 1-for-25 reverse stock split, approved by stockholders on October 22, 2025.

• Effective Date and Trading

  The reverse stock split will become effective at 4:01 p.m. Eastern Time on February 18, 2026, with shares expected to begin trading on a post-split basis on The Nasdaq Capital Market on February 19, 2026.

• Purpose: Nasdaq Listing Compliance

  The primary intent of the reverse stock split is to increase the per-share trading price to regain compliance with Nasdaq's minimum bid price requirement for continued listing.

• Impact on Shares and Fractional Shares

  Every twenty-five shares of common stock will convert into one share. The number of outstanding shares will reduce from approximately 63.3 million to 2.5 million. Stockholders entitled to fractional shares will receive a cash payment in lieu thereof.

auto_awesomeAnalysis

Intensity Therapeutics, Inc. is implementing a significant 1-for-25 reverse stock split, a measure typically undertaken by companies facing delisting from major exchanges due to a low share price. This action aims to increase the per-share trading price to meet Nasdaq's minimum bid price requirement, signaling the company's struggle to maintain its listing. While it prevents immediate delisting, reverse splits are often viewed negatively by the market as they do not fundamentally improve the company's financial health and can sometimes precede further share price erosion or dilution. Investors should monitor the stock's performance post-split and any subsequent capital-raising activities.